Breast cancer. Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: Intervention group: sinalive 70mg twice daily after breakfast and dinner , oral, for 4 courses of chemotherapy. Intervention 2: Control group: Placebo capsule for Sinaliv, produced by
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age between 18-65 y Patients with breast cancer who planned for antracycline-based chemotherapy Signing of informed consent by the patient
Exclusion criteria
Exclusion criteria: Presence of cardiomyopathy (dilated, restrictive or hypertro-phic) detected by baseline echocardiography History of hypersensitivity to silymarin or similar compounds Pregnancy and lactation Past medical history of coronary heart disease Moderate or severe aortic and/or mitral valve disease Prior chemotherapy or radiotherapy Alcohol abuse Patients on other cardiac medications such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, non-dihydropyridine calcium channel blockers, diuretics, statins or beta-blockers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular (LV) end-systolic and end-diastolic diameters (LVESD, LVEDD), systolic and diastolic function. Timepoint: Echocardiographic measurements including LVESD, LVEDD at baseline. and at 6-month after the start of chemoterapy. Method of measurement: Echocardiography measurements by a specialist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSepideh Elyasi
Mashhad University of Medical Sciences
Outcome results
None listed